Expansion drag bites Jupiter: Q1 PAT falls 15% YoY to ₹37.5 Cr despite 18% revenue growth

Jupiter Life Line Hospitals delivered a classic greenfield-expansion quarter for Q1 FY27: strong topline, shrinking bottom line. Consolidated revenue rose 18.2% YoY to ₹410.98 Cr, but net profit fell 14.5% YoY to ₹37.51 Cr (₹37.49 Cr to owners) and slipped 23% sequentially from Q4's ₹48.76 Cr. EPS came in at ₹5.72 versus ₹6.69 a year ago. With no exceptional items on either side of the comparison, the reported decline is the underlying decline — this is a genuine profit contraction, not an optics effect. The margin bridge is entirely on the cost side of the new-capacity ramp. The Dombivli hospital, commercialised in February 2026, is now in its first full cost-bearing quarter, and the fixed-cost load of new beds is landing before their revenue matures. Consolidated finance costs jumped 55% YoY to ₹12.86 Cr and depreciation rose 25% to ₹26.44 Cr, while employee, professional and other operating expenses each grew 20-26% — outpacing the 16% growth in reported operating revenue. The result: EBITDA margin (OPM) compressed to roughly 19.3% from about 22.5% a year ago, and net margin fell to ~8.9% from ~12.2%. PBT actually declined 18% YoY even as revenue expanded. Against management's own last-call guidance, the picture is two-sided: the confident revenue-growth-from-expansion thesis is intact (revenue +18% YoY, driven by the new-bed ramp toward the ~3,000-bed target across Dombivli, Pune South, Mira Road and BKC), but the near-term margin cost of that asset-heavy model is now visible in the P&L, exactly as the guidance's "Dombivli EBITDA breakeven within two years" caveat implied. No brokerage consensus for the quarter is on record yet — the Q1 FY27 earnings call is scheduled for August 3 — so vsStreet is unmarked. Alongside the numbers, the board named Harshad Purani (a 20-year company veteran) CFO effective July 31, and approved subsidiary JHPPL's ₹3.78 Cr acquisition of Sulcus Private Limited — a backward-integration move to set up an in-house IV-fluids/infusions plant near Ujjain (₹35-40 Cr planned capex over 1-2 years) aimed at lifting pharmacy margins over time.